Last reviewed · How we verify
NCT05376891
Met Non Small Cell Cancer Registry (MOMENT)
trial in Cancer in 700 participants. Currently enrolling.
28 April 2028
Quick facts
| Lead sponsor | EMD Serono Research & Development Institute, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 4 October 2022 |
| Primary completion | 28 April 2028 |
| Estimated completion | 28 April 2028 |
| Sites | 64 locations across France, Italy, Netherlands, Belgium, Austria, Sweden, United Kingdom, Germany |
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
EMD Serono Research & Development Institute, Inc. — full company profile →
Who can join
Eligibility, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, et al · · 2023 · cited 18× · PMID 37835473 · DOI 10.3390/cancers15194779 -
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapy.
Thomas M, Christopoulos P, Iams WT, Mazières J, et al · · 2025 · cited 1× · PMID 39836056 · DOI 10.57264/cer-2024-0127
Verify or expand the search:
- PubMed search for NCT05376891
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other EMD Serono Research & Development Institute, Inc. trials
Trials by the same sponsor.
- NCT07355218 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) · Phase 3 · recruiting
- NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · Phase 3 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07166601 — M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid · Phase 1 · recruiting
- NCT07097259 — A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05376891 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EMD Serono Research & Development Institute, Inc.
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05376891.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing